Follow on Google News News By Tag * Market Forecast * Revenues * Unmet Need * Drivers * Barriers * Pharma * Clinical Trials * Marketed Products * Pipeline * More Tags... Industry News News By Location Country(s) Industry News
Follow on Google News | New Report: Growth Hormone Deficiency (GHD) - Pipeline Assessment and Market Forecasts to 2017New Pharmaceuticals research report from GlobalData is now available from Fast Market Research
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. GlobalData's analysis suggests that the global Growth Hormone Deficiency (GHD) therapeutics market was worth $2.7 billion in 2009. The market is expected to grow by a CAGR (Compound Annual Growth Rate) of 2.78% during the next eight years, to reach $3.4 billion by 2017. The GHD market has been well served by synthetic growth hormone (GH), GH regulators and GH secretagogues. The major marketed products for GHD include Genotropin, Humatrope, Nutropin, Saizen and Norditropin. These are indicated for the treatment of GHD in adults and children and have an average efficacy of about 80% (overall, considering the high efficacy in children and moderate efficacy in adults), and also a good safety profile. The treatment of GHD in adults seems less effective through these options. The growth hormones are injectables. This means even a once-a-day dose will not ensure compliance as it is inconvenient to patients. Companies are now focusing on adult GHD, which will enable them to reap revenues from this growing market. The primary focus would be to provide safer and more efficacious products, with improved formulations to reduce the frequency of administration. LG Life Sciences, Althea Technologies, Ambrx Inc., Novo Nordisk and Ipsen are believed to be working on the same method of meeting the unmet need in the market. The global GHD market is heading towards a phase of continuous but slow growth. Genotropin will lose its patent in April 2013 because of which the market growth is lowered. Scope The scope of the report includes: * Annualized global growth hormone deficiency market revenues data from 2001 to 2009, forecast for eight years to 2017. * Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan. * Pipeline analysis data split across different phases by mechanism of action and emerging trends. The key classes of mechanism of action are Pegylated growth hormones, Sustained release growth hormones, long acting growth hormones, recombinant growth hormones. * Analysis of the current and future competition in the global growth hormone deficiency market. The key market players covered include Pfizer Inc., LG Life Sciences. Merck Sorono, Novo Nordisk, Ipsen, Althea Technologies, Anbrx Inc. * Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. * Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the future growth hormone deficiency market. Reasons to buy The report will enhance your decision making capability. It will allow you to: * Develop and design your in-licensing and out-licensing strategies through a review of the pipeline products and technologies and by identifying the companies with the most promising product candidates in the pipeline. * Develop business strategies by understanding the trends shaping and driving the global Growth Hormone Deficiency market. * Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Growth Hormone Deficiency market in future. * Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. * Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage. * Organize your sales and marketing efforts by identifying the market categories and segments that present the maximum opportunities for consolidation, investments and strategic partnerships. * What's the next big thing in the global Growth Hormone Deficiency market landscape? - Identify, understand and capitalize. For more information or to purchase this report, go to: - http://www.fastmr.com/ About GlobalData GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at http://www.fastmr.com/ About Fast Market Research Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156. # # # Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. End
|
| |||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number